Biogen is slashing in half the price of its controversial drug Aduhelm, which was approved by the FDA in June as the first disease-modifying…
Analysts had high hopes for anti-amyloid drug Aduhelm — the first Alzheimer’s treatment approved by the FDA in nearly two decades and the first…
Following the approval of the Alzheimer’s drug Aduhelm — and the litany of controversy surrounding it — one question that’s top of mind for…
The amyloid hypothesis—the idea that Alzheimer’s is caused by clumps of proteins known as beta-amyloid—remains unproven. But scientists are holding out hope that monoclonal…
In June, the U.S. Food and Drug Administration (FDA) approved the first new drug for treating Alzheimer’s disease in almost 20 years. The drug,…
Today, the experimental Eli Lilly drug donanemab received the FDA’s “breakthrough therapy designation” based on its potential to treat Alzheimer’s disease. The FDA granted…
Biogen’s aducanumab — a human antibody-based drug that targets beta-amyloid plaques, which are found in the brains of people with Alzheimer’s — has gone…
This weekend, Eli Lilly and Company presented detailed results of its phase 2 TRAILBLAZER-ALZ trial, showing that its investigational drug donanemab — monoclonal antibody…
(UPDATED Sat. March 13, 2021) In January, excitement rippled through the Alzheimer’s community with drugmaker Eli Lilly and Company’s announcement that their experimental drug…
The initial results from Eli Lilly and Co’s Phase 2 clinical trial for experimental Alzheimer’s drug donanemab provide much needed hope for the Alzheimer’s…
Targeting beta-amyloid protein before symptoms of cognitive decline or Alzheimer’s appear is the goal of one trial out of the National Institute on Aging…